Page 5 - Open Label Study News Today

Seven accepted poster presentations showcase our continued leadership in CAR-T cell therapy research for patients with multiple myelomaNew analysis of sustained minimal residual disease (MRD) negativity from the pivotal CARTITUDE-1 study of CARVYKTI® (ciltacabtagene autoleucel, cilta-cel) in heavily pretreated adult...

Multiple presentations will highlight the clinical utility of ZYNLONTA (loncastuximab tesirine-lpyl) in DLBCL and Cami (camidanlumab tesirine) in Hodgkin lymphoma ADC Therapeutics SA (NYSE: ADCT)

/PRNewswire/ -- Koya Medical, a healthcare company on a mission to transform lymphatic and venous care through a comprehensive suite of innovative,...

–Data results shared across facial injectables, body contouring and skincare portfolio highlights Allergan Aesthetics continued commitment to advancing...

Scientific presentations demonstrate argenx’s leadership in FcRn blockade and commitment to innovating for patients across multiple neuromuscular diseases ...

Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical meets co-primary endpoints for detecting Coronary Artery Disease (CAD) Trial also met its first key secondary

-- Approval based on MIRROR randomized controlled trial, which showed significant improvement and sustained patient response to KRYSTEXXA with methotrexate compared to KRYSTEXXA alone -- -- Trial

Investegate announcements from Redx Pharma plc, Redx Presents Poster on RXC004 at ASCO

/PRNewswire/ -- Bridge Biotherapeutics Inc. (KQ288330), a South Korean clinical-stage biotechnology company focused on developing novel drugs for cancer,...

GOTHENBURG, SE / ACCESSWIRE / April 27, 2022 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV)XVIVO proudly announces the filing of an Investigational Device Exemption (IDE) application to the US Food